Opdivo Stabilized Patient-Reported Outcomes in Phase III Study

EU CHMP issues two positive opinions for Keytruda

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted two positive opinions for Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy.

September 26, 2025

Vol.51 No.35

In Brief

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

The National Institute of Dental and Craniofacial Research awarded a $3 million grant to researchers from Henry Ford Health + Michigan State University Health Sciences to study new treatments for patients who have head-and-neck cancer caused by HPV.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Mayo Clinic researchers have established the world’s first biobank of human salivary gland tissue-organoids to study chronic dry mouth, or xerostomia, an agonizing side effect of damaged salivary glands that affects millions.

May 23, 2025

Vol.51 No.20

Clinical Roundup

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

An international clinical trial co-led by WashU Medicine found that the immunotherapy drug pembrolizumab (Keytruda) added to standard-of-care therapy improved survival for patients with locally advanced head-and-neck cancer.

May 02, 2025

Vol.51 No.17

Clinical Roundup

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.

March 14, 2025

Vol.51 No.10

Clinical Roundup

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Cedars-Sinai performed the first robot-assisted microsurgical head-and-neck cancer reconstructive surgery in the United States after the robot device received FDA approval for the procedure.

February 21, 2025

Vol.51 No.07

Opdivo Stabilized Patient-Reported Outcomes in Phase III Study

YOU MAY BE INTERESTED IN

EU CHMP issues two positive opinions for Keytruda

Henry Ford + MSU researchers granted $3M from NIH to study HPV-positive head-and-neck cancers

Mayo Clinic researchers develop first salivary gland regenerative biobank to combat chronic dry mouth

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

Chemo-immunotherapy approach shows potential benefit in advanced HPV-negative head-and-neck cancer

First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai

Renew today!

Subscriber content

Never miss an issue!

Login